3-fluoro-4-(methylsulfonylamino)benzylamine hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-fluoro-4-(methylsulfonylamino)benzylamine hydrochloride
• 英文别名: 3-fluoro-4-methylsulfonamidobenzylamine hydrochloride；(3-fluoro-4-(methylsulfonamido)phenyl)methanaminium chloride；N-(4-aminomethyl-2-fluoro-phenyl)-methanesulfonamide hydrochloride；3-fluoro-4-methanesulfonylaminobenzylamine hydrochloride；[3-Fluoro-4-(methanesulfonamido)phenyl]methylazanium;chloride；[3-fluoro-4-(methanesulfonamido)phenyl]methylazanium;chloride
• 化学式: C₈H₁₁FN₂O₂S*ClH
• 分子量: 254.713
• InChiKey: CVCVZXAEBWRRHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.08
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-fluoro-4-(methylsulfonylamino)benzylamine hydrochloride 在 四(三苯基膦)钯 、 sodium hydride 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙腈 、 mineral oil 为溶剂， 反应 2.0h， 生成 N-(4-{[6-(4-tert-butylphenyl)pyrimidin-4-ylamino]methyl}-2-fluorophenyl)methanesulfonamide
  参考文献：
  名称：

  作为新型 TRPV1 拮抗剂的 B 区修饰的二芳基烷基酰胺类似物的设计、合成和生物学评价

  摘要：

  描述了用于新型 TRPV1（瞬时受体电位通道，香草素亚家族成员 1）拮抗剂的 B 区（已知是偶极相互作用药效团、修饰的二芳基烷基酰胺类似物）的设计、合成和生物学评估。在 B 区引入了多种部分，包括胍、杂环、肉桂胺和 α-取代乙酰胺。这些类似物的 TRPV1 拮抗活性通过大鼠 DRG 神经元中的 45Ca2+ 摄取测定进行评估。特别是，α,α-二氟酰胺 53 表现出比亲本酰胺类似物 6 强 3 倍的 TRPV1 拮抗活性（IC50 = 0.058 μM）。

  DOI：

  10.1007/s12272-013-0228-x
• 作为产物：
  描述：

  2-氟-4-碘苯胺 在 吡啶 、 盐酸 、 四(三苯基膦)钯 、 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 3-fluoro-4-(methylsulfonylamino)benzylamine hydrochloride
  参考文献：
  名称：

  18 F-标记的α，α-二氟-α-（芳氧基）乙酸的合成与反应性

  摘要：

  在这项工作中，我们描述了α，α-二氟-α-（芳氧基）乙酸衍生物的18 F标记，并证明这些构件适用于18 F后氟化功能化。原羧化为18 F-二氟甲氧基芳烃提供了新的进入途径，并且该方法的价值通过偶联过程得到了进一步证明，该偶联过程导致了代表性的18 F标记的TRPV1抑制剂和TRPV1拮抗剂。

  DOI：

  10.1021/acs.orglett.6b03730

文献信息

• Synthesis and Reactivity of ¹⁸F-Labeled α,α-Difluoro-α-(aryloxy)acetic Acids
  作者：Tanatorn Khotavivattana、Samuel Calderwood、Stefan Verhoog、Lukas Pfeifer、Sean Preshlock、Neil Vasdev、Thomas L. Collier、Véronique Gouverneur

  DOI：10.1021/acs.orglett.6b03730

  日期：2017.2.3

  In this work, we describe the 18F-labeling of α,α-difluoro-α-(aryloxy)acetic acid derivatives and demonstrate that these building blocks are amenable to post-18F-fluorination functionalization. Protodecarboxylation offers a new entry to 18F-difluoromethoxyarene, and the value of this approach is further demonstrated with coupling processes leading to representative 18F-labeled TRPV1 inhibitors and

  在这项工作中，我们描述了α，α-二氟-α-（芳氧基）乙酸衍生物的18 F标记，并证明这些构件适用于18 F后氟化功能化。原羧化为18 F-二氟甲氧基芳烃提供了新的进入途径，并且该方法的价值通过偶联过程得到了进一步证明，该偶联过程导致了代表性的18 F标记的TRPV1抑制剂和TRPV1拮抗剂。
• Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
  申请人：Amorepacific Corporation

  公开号：EP1882687A1

  公开（公告）日：2008-01-30

  This present invention relates to novel compounds, of the formula (I), isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1;VR1;TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis and pancreatitis.

  这项发明涉及新化合物，其化学式为(I)，其异构体或其药学上可接受的盐作为辣椒素受体（辣椒素受体1; VR1; TRPV1）拮抗剂；以及含有该化合物的药物组合物。本发明提供了一种用于预防或治疗疾病的药物组合物，如疼痛、关节炎炎症性疾病、神经病、艾滋病相关神经病、神经损伤、神经退行性疾病、中风、包括尿失禁、膀胱过敏、膀胱炎、胃十二指肠溃疡、肠易激综合征（IBS）和炎症性肠病（IBD）、粪便紧急情况、胃食管反流病（GERD）、克罗恩病、哮喘、慢性阻塞性肺病、咳嗽、神经症/过敏/炎症性皮肤病、牛皮癣、瘙痒症、疹痒症、皮肤、眼睛或粘膜刺激、听觉过敏、耳鸣、前庭过敏、阵发性眩晕、心脏疾病如心肌缺血、与头发生长有关的疾病如脱发、脱发、鼻炎和胰腺炎。
• Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
  申请人：Hanazawa Takeshi

  公开号：US20060211741A1

  公开（公告）日：2006-09-21

  This invention provides a compound of the formula (I): wherein A and B are independently CR 12 or N; D and E are each independently CR 9 or N; R 1 represents (C 1 -C 6 )alkyl; R 2 represents hydrogen, halogen, hydroxy, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy or (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl; R 3 , R 4 , R 5 , R 6 , R 10 and R 11 each independently represent hydrogen, halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl; or R 3 and R 4 are taken together with the carbon atom to which they are attached to form a 3- to 7-membered carbocyclic ring or heterocyclic ring in which one or two non-adjacent carbon atoms are optionally replaced by an oxygen atom, a sulfur atom or NH; R 7 and R 9 each independently represent hydrogen, halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkylsulfonyl, NH 2 , [(C 1 -C 6 )alkyl]NH—, [(C 1 -C 6 )alkyl] 2 N—, H 2 N—(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-NH—(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy; H 2 N—(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 C 6 )alkyl-NH—(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl or 5- or 6-membered heterocyclic ring containing at least one nitrogen atom; R 8 represents halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkylsulfonyl, halo(C 1 -C 6 )alkylsulfinyl, halo(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkylthio, [(C 1 -C 6 )alkyl]NH— or [(C 1 -C 6 )alkyl] 2 N—; or R 7 and R 8 , when E is CR 9 , are taken together with the carbon atoms to which they are attached form a 5-8 membered carbocyclic or heterocyclic ring, in which one or two non-adjacent carbon atoms are optionally replaced by oxygen, sulfur, N or NH groups, wherein the carbocyclic ring or the heterocyclic ring is unsubstituted or substituted with one or more substituents each independently selected from the group consisting of hydroxy, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy and hydroxy(C 1 -C 6 )alkyl; and R 12 represents hydrogen, halogen, (C 1 -C 6 )alkyl or hydroxy(C 1 -C 6 )alkyl; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一个化合物的结构式(I)：其中A和B分别独立地为CR12或N；D和E分别独立地为CR9或N；R1代表(C1-C6)烷基；R2代表氢、卤素、羟基、(C1-C6)烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、(C1-C6)氧烷基或(C1-C6)氧烷基-(C1-C6)烷基；R3、R4、R5、R6、R10和R11分别独立地代表氢、卤素、(C1-C6)烷基、卤代(C1-C6)烷基、(C1-C6)氧烷基、羟基(C1-C6)烷基或(C1-C6)氧烷基-(C1-C6)烷基；或者R3和R4一起与它们连接的碳原子形成一个3-至7-成员的碳环或杂环，其中一个或两个非相邻的碳原子可以选择性地被氧原子、硫原子或NH取代；R7和R9分别独立地代表氢、卤素、(C1-C6)烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、(C1-C6)氧烷基、羟基(C1-C6)氧烷基、(C1-C6)氧烷基-(C1-C6)烷基、(C1-C6)氧烷基-(C1-C6)氧烷基、(C1-C6)烷基硫、(C1-C6)烷基亚硫基、(C1-C6)烷基磺基、NH2、[(C1-C6)烷基]NH—、[(C1-C6)烷基]2N—、H2N—(C1-C6)氧烷基、(C1-C6)烷基-NH—(C1-C6)氧烷基、[(C1-C6)烷基]2N(C1-C6)氧烷基；H2N—(C1-C6)氧烷基-(C1-C6)烷基、(C1C6)烷基-NH—(C1-C6)氧烷基-(C1-C6)烷基、[(C1-C6)烷基]2N(C1-C6)氧烷基-(C1-C6)烷基或含有至少一个氮原子的5-或6-成员杂环，R8代表卤素、(C1-C6)烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、(C1-C6)氧烷基、羟基(C1-C6)氧烷基、(C1-C6)氧烷基-(C1-C6)烷基、(C1-C6)氧烷基-(C1-C6)氧烷基、卤代(C1-C6)烷基磺基、卤代(C1-C6)烷基亚硫基、卤代(C1-C6)烷基氧基、卤代(C1-C6)烷基硫基、[(C1-C6)烷基]NH—或[(C1-C6)烷基]2N—；或者当E为CR9时，R7和R8一起与它们连接的碳原子形成一个5-8成员的碳环或杂环，其中一个或两个非相邻的碳原子可以选择性地被氧、硫、N或NH基团取代，其中碳环或杂环未取代或取代有一个或多个取代基，每个取代基独立地选自羟基、(C1-C6)烷基、(C1-C6)氧烷基和羟基(C1-C6)烷基；R12代表氢、卤素、(C1-C6)烷基或羟基(C1-C6)烷基；或其药学上可接受的盐或溶剂。这些化合物对于治疗由VR1受体过度激活引起的疾病状况，如哺乳动物中的疼痛等，是有用的。这项发明还提供了包含上述化合物的药物组合物。
• Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists
  申请人：Inoue Tadashi

  公开号：US20060100460A1

  公开（公告）日：2006-05-11

  This invention provides a compound of the formula (I): wherein R 1 represents a (C 1 -C 6 )alkyl group; R 2 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C 1 -C 6 ) alkyl group or a (C 1 -C 6 ) alkoxy group; R 3 , R 4 , R 5 and R 6 each independently represents a hydrogen atom, a (C 1 -C 6 ) alkyl, or a halogen atom; R 7 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C 1 -C 6 ) alkyl group optionally substituted with a piperidino group, a (C- 1 -C 6 )alkoxy group optionally substituted with a 3-7 membered cycloalkyl ring, a hydroxy(C 1 -C 6 )alkoxy group, a (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy group, a halo (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkylthio group, a (C 1 -C 6 )alkylsulfinyl group or a (C 1 -C 6 )alkylsulfonyl group; R 5 represents a (C 1 -C 6 )alkyl group, a halo(C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy group, a hydroxy(C 1 -C 6 )alkoxy group, a (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl group or a (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy group; or R 7 and R 8 , when adjacent to each other, taken together with the carbon atoms to which they are attached form a 5-8 membered carbocyclic or heterocyclic ring, wherein the carbocyclic ring or the heterocyclic ring is unsubstituted or substituted with one or more substituents selected from the group consisting of a hydroxy group, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy group and a hydroxy(C 1 -C 6 )alkyl group; and R 9 represents a hydrogen atom or a halogen atom; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor, such as pain or the like in mammalian. The present invention also provides a pharmaceutical composition comprising the compound of formula (I).

  这项发明提供了一种化合物，其化学式为（I）：其中R1代表（C1-C6）烷基基团；R2代表氢原子、卤原子、羟基、（C1-C6）烷基基团或（C1-C6）氧烷基基团；R3、R4、R5和R6分别独立地代表氢原子、（C1-C6）烷基或卤原子；R7代表氢原子、卤原子、羟基、（C1-C6）烷基基团，可选地取代有哌啶基团的（C1-C6）烷基基团，可选地取代有3-7个成员的环烷基环的（C-1-C6）氧烷基基团，羟基（C1-C6）氧烷基基团，（C1-C6）氧烷基（C1-C6）烷基基团，（C1-C6）氧烷基（C1-C6）氧烷基基团，卤代（C1-C6）烷基基团，（C1-C6）烷基硫基基团，（C1-C6）烷基亚硫基基团或（C1-C6）烷基砜基基团；R8代表（C1-C6）烷基基团，卤代（C1-C6）烷基基团，（C1-C6）氧烷基基团，羟基（C1-C6）氧烷基基团，（C1-C6）氧烷基（C1-C6）烷基基团或（C1-C6）氧烷基（C1-C6）氧烷基基团；或者R7和R8，当相邻时，与它们连接的碳原子一起形成一个5-8成员的脂环或杂环环，其中脂环或杂环环未取代或取代有一个或多个选自羟基、（C1-C6）烷基、（C1-C6）氧烷基和羟基（C1-C6）烷基的取代基；R9代表氢原子或卤原子；或其药学上可接受的盐或溶剂。这些化合物可用于治疗由VR1受体过度激活引起的疾病症状，如哺乳动物中的疼痛等。本发明还提供了一种包含化合物（I）的药物组成物。
• High Affinity Antagonists of the Vanilloid Receptor
  作者：Yun Wang、Tamas Szabo、Jacqueline D. Welter、Attila Toth、Richard Tran、Jiyoun Lee、Sang Uk Kang、Young-Ger Suh、Peter M. Blumberg、Jeewoo Lee

  DOI：10.1124/mol.62.4.947

  日期：2002.10.1

  The vanilloid receptor VR1 has attracted great interest as a sensory transducer for capsaicin, protons, and heat, and as a therapeutic target. Here we characterize two novel VR1 antagonists, KJM429 [ N -(4- tert -butylbenzyl)- N ′-[4-(methylsulfonylamino)benzyl]thiourea] and JYL1421 [ N -(4- tert -butylbenzyl)- N ′-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea], with enhanced activity compared with capsazepine on rat VR1 expressed in Chinese hamster ovary (CHO) cells. JYL1421, the more potent of the two novel antagonists, inhibited [3H]resiniferatoxin binding to rVR1 with an affinity of 53.5 ± 6.5 nM and antagonized capsaicin-induced calcium uptake with an EC50 of 9.2 ± 1.6 nM, reflecting 25- and 60-fold greater potencies than capsazepine. Both JYL1421 and KJM429 antagonized RTX as well as capsaicin and their mechanism was competitive. The responses to JYL1421 and KJM429 differed for calcium uptake by rVR1 induced by heat or pH. JYL1421 antagonized the response to both pH 6.0 and 5.5, whereas KJM429 antagonized at pH 6.0 but was an agonist at lower pH (<5.5). For heat, JYL1421 fully antagonized and KJM429 partially antagonized. Capsazepine showed only weak antagonism for both pH and heat. Responses of rVR1 to different activators could thus be differentially affected by different ligands. In cultured dorsal root ganglion neurons, JYL1421 and KJM429 likewise behaved as antagonists for capsaicin, confirming that the antagonism is not limited to heterologous expression systems. Finally, JYL1421 and KJM429 had little or no effect on ATP-induced calcium uptake in CHO cells lacking rVR1, unlike capsazepine. We conclude that JYL1421 is a competitive antagonist of rVR1, blocking response to all three of the agonists (capsaicin, heat, and protons) with enhanced potency relative to capsazepine.

  香草素受体VR1因其作为辣椒素、质子和热的传感转换器以及作为治疗靶点而引起了极大的兴趣。在这里，我们描述了两种新的VR1拮抗剂，KJM429[N-(4-叔丁基苄基)-N′-[4-(甲磺酰氨基)苄基]硫脲]和JYL1421[N-(4-叔丁基苄基)-N′-[3-氟-4-(甲磺酰氨基)苄基]硫脲]，它们在大鼠VR1在中国仓鼠卵巢(CHO)细胞中表达时，活性比capsazepine更强。在这两种新型拮抗剂中，JYL1421的活性更强，它抑制[3H]树脂毒素与rVR1的结合，亲和力为53.5±6.5 nM，并拮抗辣椒素诱导的钙吸收，EC50为9.2±1.6 nM，反映出比capsazepine强25倍和60倍的效力。JYL1421和KJM429均能拮抗RTX和辣椒素，其机制为竞争性。JYL1421和KJM429在钙吸收上的反应不同，前者对热或pH诱导的rVR1反应产生拮抗或激动作用。JYL1421拮抗pH 6.0和5.5的反应，而KJM429在pH 6.0时拮抗，但在更低的pH(<5.5)时为激动剂。对于热刺激，JYL1421完全拮抗，而KJM429部分拮抗。Capsazepine对pH和热的拮抗作用很弱。因此，rVR1对不同激动剂的反应可以被不同的配体不同程度地影响。在培养的背根神经节神经元中，JYL1421和KJM429同样表现为辣椒素的拮抗剂，证实了这种拮抗作用不仅限于异源表达系统。最后，与capsazepine不同，JYL1421和KJM429对缺乏rVR1的CHO细胞中的ATP诱导的钙吸收几乎没有影响。我们得出结论，JYL1421是rVR1的竞争性拮抗剂，相对于capsazepine，它阻止了对所有三种激动剂(辣椒素、热和质子)的反应，并增强了效力。